| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | 0.53 | 0.002 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.002 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.002 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |